ABSTRACT: In search for selective ligands for the muscarinic acetylcholine receptor (MR) subtype M 2 , the dimeric ligand approach, that is combining two pharmacophores in one and the same molecule, was pursued. Different types (agonists, antagonists, orthosteric, and allosteric) of monomeric MR ligands were combined by various linkers with a
INTRODUCTION
Muscarinic acetylcholine receptors (MRs) belong to the class A G-protein coupled receptor (GPCR) superfamily and comprise five receptor subtypes in humans (designated M 1 R−M 5 R). 1−4 Whereas the M 1 R, M 3 R, and M 5 R receptors were reported to couple with G q proteins, the M 2 R and M 4 R receptors bind to G i/o proteins. 5 MRs represent interesting drug targets, for instance, for the treatment of Alzheimer's disease and schizophrenia. 6, 7 Because of the high conservation of the orthosteric (acetylcholine) binding site, 8−10 there is lack of highly subtype selective (orthosteric) ligands, hampering therapeutic approaches such as the treatment of cognitive decline by centrally acting selective M 1 R agonists or M 2 R antagonists. 11 However, in addition to the orthosteric binding pocket, MRs were reported to exhibit distinct allosteric binding sites, which are less conserved and can potentially be exploited to develop subtype selective ligands. 12−17 The M 2 R was the first GPCR described to be subjected to allosteric modulation, 18−20 and several dualsteric M 2 R ligands (e.g., 7 21 and 10, 22, 23 Figure  1A ) and allosteric M 2 R modulators (e.g., 13, 20 14, 18 and 15, 24, 25 Figure 1B ) were identified.
Dimerization of GPCR ligands can result in an increased receptor affinity and improved selectivity. 26, 27 Bivalent (dimeric) ligands were described for various GPCRs, such as opioid, 28 histamine, 29, 30 dopamine, 31−33 adenosine, 33−35 and neuropeptide Y 36−38 receptors, not least to investigate receptor dimerization. Likewise, the design of dualsteric (bitopic) ligands, that is, hybrid derivatives that simultaneously address the orthosteric and allosteric sites of one and the same receptor protomer, represents an approach toward improved subtype selectivity. 19,39−42 For example, rationally designed hybrid MR ligands derived from the orthosteric agonist oxotremorine (2) and hexamethonium-like allosteric modulators (e.g., compound 16, Figure 1C ) showed increased subtype selectivity compared to 2. 43 Similarily, the MR ligand THRX-160209 (compound 17, Figure 1C ) was reported to exhibit a higher M 2 R affinity and selectivity than the corresponding monovalent ligands and was suggested to bind to the M 2 receptor in a multivalent manner. 44 Pyridobenzodiazepinone derivative 7 and the structurally closely related dibenzodiazepinone derivative 8 ( Figure 1A ) represent tricyclic M 2 R-preferring MR antagonists. 45 , 46 Trankle et al. suggested a dualsteric binding mode of 7 at the M 2 receptor, 21 and a hybrid ligand formed of 7 and allosteric modulator 14 was reported to show a pronounced positive cooperativity with 5, pointing at a new way for the development of allosteric enhancers. 47, 48 This study was aimed at the design, synthesis, and pharmacological evaluation of heterodimeric MR ligands derived from 8, comprising five combinations of 8 with reported orthosteric or allosteric MR ligands: "8−xanomeline (1)," "8−TBPB (11) ," "8−77-LH-28-1 (12)," "8−4-DAMP (3)," and "8−propantheline (4) ." Xanomeline (1) (cf. Figure  1A ) is a M 1 and M 4 receptor preferring MR agonist. 49 Compound 11 (cf. Figure 1B ) was reported to selectively activate M 1 receptors through an allosteric mechanism, as shown by mutagenesis and molecular pharmacology studies; 50−52 in other reports, 11 was described as a bitopic M 1 R ligand. 53 Likewise, compound 12 (cf. Figure 1B ) was suggested to be a bitopic M 1 R ligand. 54 MR antagonists 3 and 4 (cf. Figure 1A . 45, 55 In addition to the heterodimeric ligands, one monomeric and four homodimeric ligands derived from xanomeline, one monomeric and two homodimeric ligands derived from 8, and a monomeric ligand derived from 11 were prepared as reference compounds. Furthermore, two radiolabeled heterodimeric ligands (types "8−11" and "8−1") were prepared and characterized by saturation binding [including experiments in the presence of allosteric modulators (Schild-like analysis)], kinetic investigations, and competition-binding studies.
RESULTS AND DISCUSSION
2.1. Chemistry. Monomeric reference compound 22 and homodimeric xanomeline-derived ligand 25 were prepared by N-alkylation of homopiperazine derivative 21 using bromide 20 [followed by removal of the tert-butoxycarbonyl (Boc) group] and by alkylation of piperazine (24) using bromide 23, respectively (Scheme 1). Treatment of amine 26 with octanedioyl dichloride or decanedioyl dichloride in the presence of triethylamine yielded homodimeric xanomelinetype compounds 27 and 28, respectively. Likewise, amidation of terephthalic acid with amine 26, using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/1-hydroxybenzotriazole hydrate (HOBt) as coupling reagent, afforded homodimeric ligand 29 containing a rigid central linker moiety. N-alkylation of 21 using bromide 30, followed by removal of the Boc group, afforded TBPB derivative 31 (Scheme 1).
The "8−11" type heterodimeric ligand 34 was prepared by N-alkylation of compound 32 using bromide 33; N-alkylation 
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Article of 21 using 33, followed by removal of the Boc group yielded monomeric reference compound 35 (Scheme 2). Likewise, Nalkylation of piperazine derivatives 36 and 37, using bromide 33, gave the "8−4" type heterodimeric ligands 38 and 39. The "8−1" type heterodimeric ligand 43 was prepared through Nalkylation of compound 40 by applying a mixture of bromides 20 and 33, followed by Boc-deprotection (Scheme 2). Homodimeric ligand 41, 23 obtained as a "byproduct" (after Boc-deprotection), was isolated as well. Compound 41 was recently used as an amine precursor for the preparation of a tritium-labeled homodimeric MR ligand. 23 Amine 43 was propionylated to give congener 44. The "8−1" type ligand 46 was obtained by N-alkylation of 45 by bromide 33 (Scheme 2). The "8−3" type heterodimeric ligand 48 and the "8−12" type ligand 50 were synthesized by alkylation of compound 47 using bromide 33 and by alkylation of amine 9 22 (cf. Figure 1A ) using bromide 49, respectively (Scheme 2). Treatment of 40 with a mixture of bromides 30 and 33, followed by Bocdeprotection, gave the "8−11" type heterodimeric ligand 51, which contains a rigid homopiperazine moiety in between the pharmacophores. As in the case of the synthesis of 43, homodimeric "byproduct" 41 was isolated. Propionylation of 51 gave congener 52 (Scheme 2 Table  1 .
All compounds containing a dibenzodiazepinone moiety showed high M 2 R affinity (pK i > 8.3). Whereas homodimeric derivatives (25, 27−29) of MR agonist 1 exhibited an increased M 2 R affinity (pK i > 7.7) compared to the parent compound (pK i of 1: 6.55, see Table 3 ); the opposite was found in the case of MR antagonist 3 [pK i = 7.09 ± 0.04, mean ± standard error of the mean (SEM) from two independent experiments] and a homodimeric derivative of 3 (compound 54, pK i = 6.05, Table  1 ). The "8−1" type heterodimeric ligand 46 displayed the highest M 2 R affinity (pK i = 10.14, Figure 1A) , 45 the MR antagonist tripitramine 56 containing three pyridobenzodiazepinone moieties, as well as the recently reported dibenzodiazepinone derivatives 10 and 19 (cf. Figure  1C) . 23 Figure 3A ), but completely suppressed the effect of CCh when studied in the antagonist mode ( Figure 3B ), revealing that the combination of the agonist xanomeline (1) with a dibenzodiazepinone-type antagonist in one molecule (e.g., 44) resulted in a loss of agonistic activity. Interestingly, homodimeric ligand 25, which is derived from MR agonist 1, proved to be a M 2 R antagonist in contrast to parent compound 1 ( Figure 3 ). The pK b values of 44, 46, and 64 (cf. Figure 3B) were lower compared to the respective pK i values (cf. Figure 4A ). Additionally, the tritiated derivative of heterodimeric ligand 64 was prepared from 63 and [ Figure 4C, 23 the extent of unspecific binding strongly depended on the assay conditions: in the case of experiments performed at intact adherent cells (white/transparent 96-well plates), unspecific binding was considerably higher compared to experiments performed at cell homogenates, which preclude the unspecific binding of the radioligand to the microplate ( Figure 5 ). 23 The apparent K d values amounted to 1.0 and 0.081 nM (cell homogenates, Table 2 ). As orthosteric antagonist 6 (used to determine unspecific binding) completely Figure  6D , Table 2 ). An incomplete ligand dissociation, which might be attributed to conformational adjustments of the receptor upon ligand binding 57 or an enhanced rebinding capability of the dimeric ligand, 58 was also reported for the homodimeric Slope different from unity (P < 0.05).
Article 10, or 14. Likewise, orthosteric ligands 1 and 6, dualsteric ligands 7 and 10, as well as allosteric modulators 13−15 (cf. Figure 7B ), was in accordance with the reported M 2 R binding data of 14 (pK X 7.50 59 ). 22 suggested a minor influence of the second pharmacophore on M 2 R binding, indicating that the high M 2 R affinity of these compounds is mediated by the "dibenzodiazepinone" pharmacophore, which binds most likely to the orthosteric binding site of the M 2 R. This is supported by the proposed binding mode of 10 and 19 at the M 2 R, 23 
CONCLUSIONS

ACS Omega
Article as a second pharmacophore (43, 44, 46, 60 , and 61) proved to be M 2 R-preferring ligands. Moreover, the prototypical heterodimeric ligands 44 and 46 were shown to be M 2 R antagonists (cf. Figure 3) . Concerning the "8−1" type heterodimeric ligands, one can speculate about the contribution of the pharmacophore of 1 to M 2 R binding because the homodimeric derivatives of 1 (compounds 25, 27−29) exhibited considerably higher M 2 R affinities compared to 1. This work confirms that dibenzodiazepinone-type MR ligands represent a promising class of compounds for the development of highly selective M 2 R ligands with a high receptor affinity based on the dualsteric ligand approach.
METHODS
4.1. General Experimental Conditions. Reagents and chemicals for synthesis were purchased from Acros Organics (Geel, Belgium), Iris Biotech (Marktredwitz, Germany), Alfa Aesar (Karlsruhe, Germany), Merck (Darmstadt, Germany), Sigma (Munich, Germany), or TCI Europe (Zwijndrecht, Belgium). Technical grade solvents (acetone, ethyl acetate, light petroleum (40−60°C), and CH 2 Cl 2 ) were distilled before use. Deuterated solvents for nuclear magnetic resonance (NMR) spectroscopy were from Deutero (Kastellaun, Germany). Acetonitrile for HPLC (gradient grade) was obtained from Merck or Sigma. Anhydrous DMF was purchased from Sigma. CCh (Sigma) and compounds 6 (Sigma), 7 (Abcam, Cambridge, UK), 13 (Sigma), 14 (Sigma), and 15 (Absource Diagnostic, Munich, Germany) were purchased from commercial suppliers. 
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Article Millipore water was used throughout for the preparation of buffers and HPLC eluents. If moisture-free conditions were required, reactions were performed in dried glassware under an inert atmosphere (argon). Anhydrous THF was obtained by distillation over sodium, and anhydrous CH 2 Cl 2 was prepared by distillation over P 2 O 5 after predrying over CaCl 2 . Reactions were monitored by thin-layer chromatography using aluminum plates coated with silica gel (Merck silica gel 60 F 254 , thickness 0.2 mm). Spots were detected by ultraviolet (UV) light (254 or 366 nm) or by staining using 0.3% solution of ninhydrin in nbutanol (amines) or iodine. Column chromatography was performed in glass columns on silica gel (Merck silica gel 60, 63−200 μm). Flash chromatography was performed on an Intelli Flash-310 Flash-Chromatography Workstation (Varian, Darmstadt, Germany). Polypropylene reaction vessels (1.5 or 2 mL) with a screw cap (Sud-Laborbedarf, Gauting, Germany) were used for the synthesis of radioligands ( Microwave-assisted reactions were performed with an Initiator 2.0 synthesizer (Biotage, Uppsala, Sweden). NMR spectra were recorded on a Bruker AVANCE 300 (7.05 T), Bruker AVANCE III HD 400 (9.40 T), or a Bruker AVANCE III HD 600 spectrometer equipped with a cryogenic probe (14.1 T) (Bruker, Karlsruhe, Germany). Abbreviations for the multiplicities of the signals are s (singlet), d (doublet), t (triplet), dd (doublet-of-doublet), q (quartet), m (multiplet), and brs (broad-singlet). Infrared (IR) spectra were measured with a Nicolet 380 FT-IR spectrophotometer (Thermo Electron Corporation). Low-resolution mass spectrometry was performed on a Finnigan SSQ 710A instrument [chemical ionization mass spectrometry (CI-MS, Thermo Finnigan, San Jose, CA). High-resolution mass spectrometry (HRMS) analysis was performed on an Agilent 6540 UHD AccurateMass Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA) using an electrospray ionization source. Preparative HPLC was performed on a system from Knauer (Berlin, Germany) consisting of two K-1800 pumps and a K-2001 detector. Except for compound 54, a Kinetex-XB C18 column, 5 μm, 250 × 21 mm (Phenomenex, Aschaffenburg, Germany) served as the stationary phase at a flow rate of 15 mL/min. For the purification of 54, a Nucleodur 100-5 C18 column, 5 μm, saturation-binding binding kinetics radioligand c Association rate constant ± propagated error, calculated from k obs (nonlinear regression), k off (nonlinear regression), and the applied radioligand concentration (cf. Radioligand Binding). 
Article 250 × 21 mm (Macherey-Nagel, Duren, Germany) was used as the stationary phase at a flow rate of 15 mL/min. Mixtures of acetonitrile and 0.1% aq TFA were used as the mobile phase, and a detection wavelength of 220 nm was used throughout. Lyophilization of the collected fractions was performed with an Alpha 2-4 LD apparatus (Martin Christ, Osterode am Harz, Germany). Except for compound 54, analytical HPLC analysis (purity control) was performed on a system from MerckHitachi Annotation concerning the NMR spectra ( 
